Another Major Role for Dietary Sodium Reduction
Improving Blood Pressure Control in Patients With Resistant Hypertension

Lawrence J. Appel

Resistant hypertension, defined as blood pressure (BP) above goal in spite of the current use of 3 antihypertensive agents of different classes, is a common problem in general medical practice as well as specialty hypertension clinics. The prevalence of resistant hypertension is uncertain. Recent trials suggest a prevalence of 20% to 30%,¹ which might be an overestimate because of selection procedures and enrollment criteria. If one applies a prevalence of 10% to the estimated 65 million Americans with hypertension, then ∼6.5 million Americans have resistant hypertension. The cause of this condition is almost always multifactorial. Common factors include lifestyle factors (eg, excess sodium intake, obesity, high alcohol intake), drug-related causes (eg, non-narcotic analgesics, sympathetic agents), and secondary causes of hypertension (eg, obstructive sleep apnea, primary aldosteronism, chronic kidney disease, and renal artery stenosis). In contrast to most of these conditions, a high sodium intake is ubiquitous and provides an opportunity to improve BP control, even when other factors coexist.

Evidence linking salt (sodium chloride) intake with elevated BP is substantial and indisputable. Sodium reduction has been shown to lower BP in persons with prehypertension, untreated Stage 1 hypertension, and medication-treated hypertension.³ The effects of sodium reduction in hypertensive individuals on multiple medications, with or without controlled BP, has received scant attention, probably because of challenges related to accrual of participants and ethical issues related to prolonged assignment to a high-sodium control condition. In this issue of Hypertension, Pimenta and colleagues document the benefits of sodium reduction in patients with resistant hypertension.⁴

Pimenta and colleagues are to be congratulated for designing and implementing this challenging but informative and likely influential study. One cannot overestimate the logistical difficulties of recruiting eligible and interested participants, feeding them every meal over an extended period, and collecting a plethora of measurements. In brief, Pimenta and colleagues conducted a 2-period, randomized, crossover feeding study that compared 2 levels of sodium intake (250 mmol [5700 mg] per day versus 50 mmol [1150 mg] per day). Each feeding period lasted 1 week. Participants were 12 patients with resistant hypertension (50% black, 67% female, mean age of 55.5 years, mean body mass index of 32.9 kg/m²). At baseline, participants had mean office BP of 145.8/83.9 mm Hg on an average of 3.4 antihypertensive medications; baseline 24-hour urine sodium excretion was 194.7 mmol (4470 mg) per day.

The results were striking. Compared to the higher level of sodium intake, the lower level of sodium intake reduced mean (95% CI) office systolic BP by 22.7 mm Hg (11.8, 33.5) and office diastolic BP by 9.1 mm Hg (3.1, 15.1). Reductions in daytime, nighttime, and 24-hour ambulatory BP were virtually identical to reductions in office BP. The extent of BP reduction vastly exceeds corresponding levels of BP reduction observed in trials of hypertensive individuals not on medication (see Table for a comparison of trial results with corresponding data from untreated hypertensive individuals enrolled in the Dietary Approaches to Stop Hypertension-Sodium [DASH-Sodium trial]).⁵

The main limitations of the trial by Pimenta and colleagues are its size (only 12 participants) and the duration of feeding

### Table. Comparison of Two Trials of Sodium Reduction

<table>
<thead>
<tr>
<th>Feature</th>
<th>Trial by Pimenta et al⁴ (n=12)</th>
<th>DASH-Sodium Trial With Untreated Hypertension⁵ (n=168)</th>
</tr>
</thead>
<tbody>
<tr>
<td>% on antihypertensive medication</td>
<td>100%</td>
<td>0%</td>
</tr>
<tr>
<td>% black</td>
<td>50%</td>
<td>61%</td>
</tr>
<tr>
<td>% female</td>
<td>67%</td>
<td>63%</td>
</tr>
<tr>
<td>Mean±SD age, y</td>
<td>55.5±9.4</td>
<td>50.3±10.6</td>
</tr>
<tr>
<td>Mean±SD baseline sodium excretion, mmol/day</td>
<td>194.7±68.6</td>
<td>153.4±74.8</td>
</tr>
<tr>
<td>Highest and lowest sodium levels provided during feeding, mmol/day</td>
<td>250 vs 50</td>
<td>150 vs 50</td>
</tr>
<tr>
<td>Mean±SD baseline systolic BP, mm Hg</td>
<td>145.8±10.8</td>
<td>143.0±7.8</td>
</tr>
<tr>
<td>Mean±SD baseline diastolic BP, mm Hg</td>
<td>83.9±11.2</td>
<td>88.5±4.5</td>
</tr>
<tr>
<td>Mean (95% CI) systolic BP reduction, mm Hg</td>
<td>22.7 (11.8, 33.5)</td>
<td>8.3 (6.6, 10.0)</td>
</tr>
<tr>
<td>Mean (95% CI) diastolic BP reduction, mm Hg</td>
<td>9.1 (3.1, 15.1)</td>
<td>4.1 (3.3, 5.4)</td>
</tr>
</tbody>
</table>

Data taken from Trial by Pimenta et al⁴ of patients with resistant hypertension and the DASH-Sodium Trial⁵ of patients with untreated hypertension.
Replication of the study is clearly warranted. Its strengths include superb implementation, which achieved the intended contrast in sodium intake (24-hour urine sodium excretion of 252.2 versus 46.1 mmol/d), and the large number of outcome variables, including ambulatory BP, pulse wave velocity measurements, and measurements of renin–angiotensin system activity. In the context of other human research on dietary sodium intake and BP, which has focused almost exclusively on individuals who were on no or few antihypertensive medications, these results extend the role of sodium reduction to an important but understudied population.

Were the large BP reductions expected? Perhaps. Some might anticipate that sodium reduction would lower BP substantially, because all participants were taking either an angiotensin converting enzyme inhibitor or angiotensin receptor blocker. Medications that block the renin angiotensin system lead to increased salt sensitivity. However, I was surprised by the extent of BP reduction, which was roughly the equivalent of adding 2 antihypertensive medications. First, trial participants were already taking a large number of antihypertensive medications (mean of 3.4 drugs per day). Subadditivity commonly occurs when multiple effective therapies are implemented simultaneously. Second, all participants were taking hydrochlorothiazide. In this setting, one might expect an attenuated effect from dietary sodium reduction given that participants were already on volume-reducing therapy. Nonetheless, participants must have still had some degree of volume expansion, likely quite large, given the pattern of findings—namely, higher plasma renin activity and reductions in weight, brain natriuretic peptide, and creatinine clearance when sodium intake was reduced. The relatively high level of nighttime BP compared to daytime BP (mean nighttime BP of 146.8 versus mean daytime BP of 152.3 mm Hg on the higher sodium level) also suggests a volume-expanded state. Third, despite the diagnosis of resistant hypertension, mean office systolic BP of 145.8 mm Hg was just above the treatment goal of 140 mm Hg, whereas the mean office diastolic BP of 83.9 mm Hg was well below the treatment goal of 90 mm Hg. In general, trials that enroll persons with lower levels of BP observe less BP reduction from active therapy than trials enrolling persons with higher levels of BP. Fourth, the background diet of the participants was rich in potassium (4100 mg [106 mmol] per day). The content of commercially prepared foods.

In summary, data presented by Pimenta and colleagues strongly suggest that persons with resistant hypertension are extremely sensitive to the BP-lowering effects of sodium reduction. The observed reductions in BP were huge—roughly equivalent to adding 2 antihypertensive medications. Although clinicians commonly focus on the next drug (eg, aldosterone blocking therapy) and sometimes a device (eg, Rheos systems that stimulate carotid baroreceptors), a renewed and aggressive emphasis on lifestyle modification, specifically sodium reduction, is warranted in patients with resistant hypertension and uncontrolled BP.

Disclosures
Dr Appel has received research grants from NIDDK, NHLBI, and King-Monarch Pharmaceuticals.

References
2. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to

(only 1 week per feeding period). Replication of the study is clearly warranted. Its strengths include superb implementation, which achieved the intended contrast in sodium intake (24-hour urine sodium excretion of 252.2 versus 46.1 mmol/d), and the large number of outcome variables, including ambulatory BP, pulse wave velocity measurements, and measurements of renin–angiotensin system activity. In the context of other human research on dietary sodium intake and BP, which has focused almost exclusively on individuals who were on no or few antihypertensive medications, these results extend the role of sodium reduction to an important but understudied population.

Were the large BP reductions expected? Perhaps. Some might anticipate that sodium reduction would lower BP substantially, because all participants were taking either an angiotensin converting enzyme inhibitor or angiotensin receptor blocker. Medications that block the renin angiotensin system lead to increased salt sensitivity. However, I was surprised by the extent of BP reduction, which was roughly the equivalent of adding 2 antihypertensive medications. First, trial participants were already taking a large number of antihypertensive medications (mean of 3.4 drugs per day). Subadditivity commonly occurs when multiple effective therapies are implemented simultaneously. Second, all participants were taking hydrochlorothiazide. In this setting, one might expect an attenuated effect from dietary sodium reduction given that participants were already on volume-reducing therapy. Nonetheless, participants must have still had some degree of volume expansion, likely quite large, given the pattern of findings—namely, higher plasma renin activity and reductions in weight, brain natriuretic peptide, and creatinine clearance when sodium intake was reduced. The relatively high level of nighttime BP compared to daytime BP (mean nighttime BP of 146.8 versus mean daytime BP of 152.3 mm Hg on the higher sodium level) also suggests a volume-expanded state. Third, despite the diagnosis of resistant hypertension, mean office systolic BP of 145.8 mm Hg was just above the treatment goal of 140 mm Hg, whereas the mean office diastolic BP of 83.9 mm Hg was well below the treatment goal of 90 mm Hg. In general, trials that enroll persons with lower levels of BP observe less BP reduction from active therapy than trials enrolling persons with higher levels of BP. Fourth, the background diet of the participants was rich in potassium (4100 mg [106 mmol] per day). The content of commercially prepared foods.

In summary, data presented by Pimenta and colleagues strongly suggest that persons with resistant hypertension are extremely sensitive to the BP-lowering effects of sodium reduction. The observed reductions in BP were huge—roughly equivalent to adding 2 antihypertensive medications. Although clinicians commonly focus on the next drug (eg, aldosterone blocking therapy) and sometimes a device (eg, Rheos systems that stimulate carotid baroreceptors), a renewed and aggressive emphasis on lifestyle modification, specifically sodium reduction, is warranted in patients with resistant hypertension and uncontrolled BP.

Disclosures
Dr Appel has received research grants from NIDDK, NHLBI, and King-Monarch Pharmaceuticals.

References
2. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to


KEY WORDS: sodium ■ salt ■ resistant hypertension ■ blood pressure
Another Major Role for Dietary Sodium Reduction: Improving Blood Pressure Control in Patients With Resistant Hypertension

Lawrence J. Appel

Hypertension. 2009;54:444-446; originally published online July 20, 2009;
doi: 10.1161/HYPERTENSIONAHA.109.132944

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2009 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/54/3/444

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org/subscriptions/